Experts in breast oncology gather for a discussion on important datasets in breast cancer recently presented at the ESMO 2021 Virtual Meeting.
Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive.
EP. 1: Updates in HER2+ Breast Cancer from ESMO 2021
Expert oncologists discuss data from several phase 2 and phase 3 trials presented at ESMO 2021 on the use of trastuzumab deruxtecan for HER2-positive breast cancer and how it impacts their practices.
EP. 2: Interesting Trials in HER2+ Breast Cancer
Key opinion leaders review data from the phase III TULIP trial in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer and the ExteNET study on extended adjuvant treatment with neratinib.
EP. 3: Updates in HR+/HER2- Breast Cancer: The MONALEESA-2 Trial
Breast oncologists explain results from the phase III MONALEESA-2 trial presented at ESMO 2021, and its clinical implications.
EP. 4: ESMO 2021: Updates in Triple Negative Breast Cancer
Drs Joyce O’Shaughnessy, Sara Tolaney, Sara Hurvitz, and Mark Pegram examine recent trial data from ESMO 2021 on triple-negative breast cancer.
Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer
T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer
Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer
Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer